Cargando…

Laboratory evaluations of the 3-month efficacy of oral lotilaner (Credelio™) against experimental infestations of dogs with the Australian paralysis tick, Ixodes holocyclus

BACKGROUND: From three days following host attachment, the Australian paralysis tick, Ixodes holocyclus, secretes a neurotoxin that annually causes paralysis in approximately 10,000 domestic pets. Lotilaner, a novel isoxazoline formulated in a chewable flavoured tablet (Credelio(TM)), produces rapid...

Descripción completa

Detalles Bibliográficos
Autores principales: Baker, Kim, Ellenberger, Claudia, Murphy, Martin, Cavalleri, Daniela, Seewald, Wolfgang, Drake, Jason, Nanchen, Steve, Hacket, Kristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116354/
https://www.ncbi.nlm.nih.gov/pubmed/30157914
http://dx.doi.org/10.1186/s13071-018-3061-8
_version_ 1783351587222061056
author Baker, Kim
Ellenberger, Claudia
Murphy, Martin
Cavalleri, Daniela
Seewald, Wolfgang
Drake, Jason
Nanchen, Steve
Hacket, Kristina
author_facet Baker, Kim
Ellenberger, Claudia
Murphy, Martin
Cavalleri, Daniela
Seewald, Wolfgang
Drake, Jason
Nanchen, Steve
Hacket, Kristina
author_sort Baker, Kim
collection PubMed
description BACKGROUND: From three days following host attachment, the Australian paralysis tick, Ixodes holocyclus, secretes a neurotoxin that annually causes paralysis in approximately 10,000 domestic pets. Lotilaner, a novel isoxazoline formulated in a chewable flavoured tablet (Credelio(TM)), produces rapid onset of acaricidal activity in dogs, with an efficacy duration of at least one month. Two studies were performed to determine the efficacy of lotilaner against I. holocyclus infestations over 3 months. METHODS: Both studies included 16 dogs, ranked according to I. holocyclus counts on Day -5 (from infestations on Day -8) and blocked into pairs. One dog in each pair was randomized to be a sham-treated control, the other to receive lotilaner at a minimum dose rate of 20 mg/kg on Day 0. Dogs were dosed in a fed state. Infestations were performed in both studies on Days -8 (to determine the tick carrying capacity of each dog) -1, 28, 56, 70, 77 and 84, and additionally in Study 1 on Day 91, in Study 2 on Days 14 and 42. In Study 1, ticks were counted and assessed as alive or dead at 24, 48 and 72 h post-initial infestation and post-subsequent re-infestations. In study 2, ticks were counted at 24, 48 and 72 h post-dosing or post-re-infestation. Efficacy was determined by the percent reduction in live attached tick counts in the lotilaner group compared to control. RESULTS: Within 48 h post-treatment in Study 1 and within 72 h post-treatment in Study 2 all lotilaner-group dogs were free of live ticks. By 72 h post-infestation, efficacy in Study 1 remained at 100% through Day 87, except on Day 31 when a single tick was found on one dog, and through Day 59 in Study 2. Efficacy exceeded 95% through the final assessment in each study (Days 94 and 87 in Studies 1 and 2, respectively). CONCLUSION: These results demonstrate that lotilaner quickly kills existing I. holocyclus infestations. By providing 95.3–100.0% protection through at least 87 days post-treatment, lotilaner can be a valuable tool in reducing the risk of tick paralysis in dogs.
format Online
Article
Text
id pubmed-6116354
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-61163542018-09-04 Laboratory evaluations of the 3-month efficacy of oral lotilaner (Credelio™) against experimental infestations of dogs with the Australian paralysis tick, Ixodes holocyclus Baker, Kim Ellenberger, Claudia Murphy, Martin Cavalleri, Daniela Seewald, Wolfgang Drake, Jason Nanchen, Steve Hacket, Kristina Parasit Vectors Research BACKGROUND: From three days following host attachment, the Australian paralysis tick, Ixodes holocyclus, secretes a neurotoxin that annually causes paralysis in approximately 10,000 domestic pets. Lotilaner, a novel isoxazoline formulated in a chewable flavoured tablet (Credelio(TM)), produces rapid onset of acaricidal activity in dogs, with an efficacy duration of at least one month. Two studies were performed to determine the efficacy of lotilaner against I. holocyclus infestations over 3 months. METHODS: Both studies included 16 dogs, ranked according to I. holocyclus counts on Day -5 (from infestations on Day -8) and blocked into pairs. One dog in each pair was randomized to be a sham-treated control, the other to receive lotilaner at a minimum dose rate of 20 mg/kg on Day 0. Dogs were dosed in a fed state. Infestations were performed in both studies on Days -8 (to determine the tick carrying capacity of each dog) -1, 28, 56, 70, 77 and 84, and additionally in Study 1 on Day 91, in Study 2 on Days 14 and 42. In Study 1, ticks were counted and assessed as alive or dead at 24, 48 and 72 h post-initial infestation and post-subsequent re-infestations. In study 2, ticks were counted at 24, 48 and 72 h post-dosing or post-re-infestation. Efficacy was determined by the percent reduction in live attached tick counts in the lotilaner group compared to control. RESULTS: Within 48 h post-treatment in Study 1 and within 72 h post-treatment in Study 2 all lotilaner-group dogs were free of live ticks. By 72 h post-infestation, efficacy in Study 1 remained at 100% through Day 87, except on Day 31 when a single tick was found on one dog, and through Day 59 in Study 2. Efficacy exceeded 95% through the final assessment in each study (Days 94 and 87 in Studies 1 and 2, respectively). CONCLUSION: These results demonstrate that lotilaner quickly kills existing I. holocyclus infestations. By providing 95.3–100.0% protection through at least 87 days post-treatment, lotilaner can be a valuable tool in reducing the risk of tick paralysis in dogs. BioMed Central 2018-08-29 /pmc/articles/PMC6116354/ /pubmed/30157914 http://dx.doi.org/10.1186/s13071-018-3061-8 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Baker, Kim
Ellenberger, Claudia
Murphy, Martin
Cavalleri, Daniela
Seewald, Wolfgang
Drake, Jason
Nanchen, Steve
Hacket, Kristina
Laboratory evaluations of the 3-month efficacy of oral lotilaner (Credelio™) against experimental infestations of dogs with the Australian paralysis tick, Ixodes holocyclus
title Laboratory evaluations of the 3-month efficacy of oral lotilaner (Credelio™) against experimental infestations of dogs with the Australian paralysis tick, Ixodes holocyclus
title_full Laboratory evaluations of the 3-month efficacy of oral lotilaner (Credelio™) against experimental infestations of dogs with the Australian paralysis tick, Ixodes holocyclus
title_fullStr Laboratory evaluations of the 3-month efficacy of oral lotilaner (Credelio™) against experimental infestations of dogs with the Australian paralysis tick, Ixodes holocyclus
title_full_unstemmed Laboratory evaluations of the 3-month efficacy of oral lotilaner (Credelio™) against experimental infestations of dogs with the Australian paralysis tick, Ixodes holocyclus
title_short Laboratory evaluations of the 3-month efficacy of oral lotilaner (Credelio™) against experimental infestations of dogs with the Australian paralysis tick, Ixodes holocyclus
title_sort laboratory evaluations of the 3-month efficacy of oral lotilaner (credelio™) against experimental infestations of dogs with the australian paralysis tick, ixodes holocyclus
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116354/
https://www.ncbi.nlm.nih.gov/pubmed/30157914
http://dx.doi.org/10.1186/s13071-018-3061-8
work_keys_str_mv AT bakerkim laboratoryevaluationsofthe3monthefficacyoforallotilanercredelioagainstexperimentalinfestationsofdogswiththeaustralianparalysistickixodesholocyclus
AT ellenbergerclaudia laboratoryevaluationsofthe3monthefficacyoforallotilanercredelioagainstexperimentalinfestationsofdogswiththeaustralianparalysistickixodesholocyclus
AT murphymartin laboratoryevaluationsofthe3monthefficacyoforallotilanercredelioagainstexperimentalinfestationsofdogswiththeaustralianparalysistickixodesholocyclus
AT cavalleridaniela laboratoryevaluationsofthe3monthefficacyoforallotilanercredelioagainstexperimentalinfestationsofdogswiththeaustralianparalysistickixodesholocyclus
AT seewaldwolfgang laboratoryevaluationsofthe3monthefficacyoforallotilanercredelioagainstexperimentalinfestationsofdogswiththeaustralianparalysistickixodesholocyclus
AT drakejason laboratoryevaluationsofthe3monthefficacyoforallotilanercredelioagainstexperimentalinfestationsofdogswiththeaustralianparalysistickixodesholocyclus
AT nanchensteve laboratoryevaluationsofthe3monthefficacyoforallotilanercredelioagainstexperimentalinfestationsofdogswiththeaustralianparalysistickixodesholocyclus
AT hacketkristina laboratoryevaluationsofthe3monthefficacyoforallotilanercredelioagainstexperimentalinfestationsofdogswiththeaustralianparalysistickixodesholocyclus